What if the biggest barrier to rare disease treatment isn’t innovation… but affordability?
The more generic options available following orphan medicine loss of exclusivity, the greater the cost savings.
Read more
Oranda Therapeutics Secures Start-Up Funding and First Marketing Authorisation
Investors back new Irish-headquartered company to support its mission, championing accessibility to rare disease medicines.
Read moreOTD-NP-GBR-00005 | March 2026